Topic: High-Content Imaging

Liver toxicity can emerge late in drug development when early assays fail to capture human biology, exposure or injury mechanisms. This webinar introduces Axiom’s hepatic profiling approach, combining multicellular liver systems, high-content imaging, transcriptomics, proteomics and ADME measurements. Its reasoning agent integrates those results with partner assays, chemical-series context, exposure estimates and clinical evidence to assess mechanistic liver-safety risks. Rather than using a single cell-toxicity score, the approach develops interpretable, series-specific structure–toxicity hyp